Analysts Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) Target Price at $15.75

Ventyx Biosciences, Inc. (NASDAQ:VTYX) has received a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the firm, MarketBeat reports. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $15.75.

A number of research firms have commented on VTYX. Oppenheimer reduced their price target on shares of Ventyx Biosciences from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Thursday, June 6th. HC Wainwright restated a “neutral” rating and issued a $6.00 price target on shares of Ventyx Biosciences in a research report on Thursday, June 13th.

Ventyx Biosciences Trading Up 1.7 %

Shares of Ventyx Biosciences stock opened at $2.95 on Friday. The firm’s 50-day simple moving average is $3.22 and its 200-day simple moving average is $4.15. Ventyx Biosciences has a twelve month low of $1.87 and a twelve month high of $38.20.

Ventyx Biosciences (NASDAQ:VTYX) last issued its earnings results on Thursday, May 9th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.05. During the same quarter last year, the business earned ($0.68) EPS. On average, equities analysts forecast that Ventyx Biosciences will post -2.31 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ventyx Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the business. Farallon Capital Management LLC bought a new stake in shares of Ventyx Biosciences during the first quarter worth approximately $17,435,000. Vanguard Group Inc. raised its holdings in Ventyx Biosciences by 11.7% in the third quarter. Vanguard Group Inc. now owns 2,662,671 shares of the company’s stock worth $92,475,000 after purchasing an additional 277,906 shares during the period. Redmile Group LLC raised its holdings in Ventyx Biosciences by 944.4% in the first quarter. Redmile Group LLC now owns 2,164,126 shares of the company’s stock worth $11,903,000 after purchasing an additional 1,956,923 shares during the period. Opaleye Management Inc. raised its holdings in Ventyx Biosciences by 12.7% in the first quarter. Opaleye Management Inc. now owns 1,285,000 shares of the company’s stock worth $7,068,000 after purchasing an additional 145,000 shares during the period. Finally, First Light Asset Management LLC acquired a new stake in Ventyx Biosciences in the first quarter worth $3,437,000. 97.88% of the stock is owned by institutional investors.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.